Slide 1: Investor Presentation August 2023
ACTIONS FSGS CLINICAL STUDY @ Dimerix (ASX:DXB) Investor Presentation August 2023 For personal use only Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs Authorised for lodgement by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements For personal use only This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be ma
Slide 3: Late stage, phase 3 clinical development asset
Late stage, phase 3 clinical development asset Orphan Drug status providing protection through data exclusivity? for min 7-10 years, in addition to comprehensive patent/IP strategy Near term Phase 3 interim analysis results announced (“15Mar24') Advanced partnering Estimated >3b global market negoti
Slide 4: Significantly de-risked, late-stage development program
Significantly de-risked, late-stage development program = Cc jo) ®o 12) =) _ Strong safety profile!— no Proven efficacy'in Phase 2 Ghnvicted = (40) material adverse events in studies — Met primary and studies?- expect no further Cc Phase 1/2 secondary endpoints work required by FDA je) i?) = 2 a jos
Slide 5: Development pipeline
Development pipeline Program Indication Core focus { Focal Segmental Glomerular Sclerosis (FSGS) DMX-200 Diabetic Kidney Disease DMX-700 Chronic Obstructive Pulmonary Disease (COPD) DMX-xxx Undisclosed (multiple) For personal use only @ Dimerix
Slide 6: For personal use only
For personal use only • • • • • • • • •
Slide 7: For personal use only
• • ▪ For personal use only ▪ ▪ • $14.00 $12.00 $10.00 Share Price $8.00 $6.00 $4.00 $2.00 $0.00 Neuren Pharmaceuticals Limited (ASX:NEU) - Share Pricing
Slide 8: For personal use only
For personal use only • • • • • • • ▪ ▪ ▪ ▪ ▪ ▪ ▪
Slide 9: FSGS market size
FSGS market size For personal use only FSGS 7MM market > Assuming US$9,900k/month as size estimated to be example pricing in the US (same pricing as Sparsentan in IgAN)? U S 3 Dp.at > Current market specifically for FSGS does not exist FSGS Market Size Region Estimated diagnosed patients iS p.a g (2
Slide 10: Competitive landscape in FSGS
Competitive landscape in FSGS Da ce Phase 1 Phase 2 Phase 3 Company fo) nn D DMX-200 @ Dimerix > River 3 Renal Onn nan nanan eee nen panne ntnnennenn nnn nnnnnnnnnnnnnnnn anna nnennnenenneneonennenennnntnntnennesnenenannennenntnnennennennensnnennenntntnntnatnesennenaenennennennennennens 7 VX-147 Ver
Slide 11: Licensing deal sizes and upfront payments
1600 AstraZeneca + Cincor (Global) For personal use only Ph2, $522M upfront 1400 • • 1200 Travere + CSL Vifor (EU, UK) Ph3, $55M upfront Roche + Ionis (Global) Ph3, $55M upfront 1000 Novo Nordisk + Ventus (Global) Deal size (US$M) Cyclerion + Akebia (Global) Ph1, $70M upfront Ph2, $3M upfront 800 Ka
Slide 12: For personal use only
For personal use only • • • • • • • • • • • • • •
Slide 13: Phase 3 clinical trial ACTION3
PHASE 3 CLINICAL TRIAL ACTIGNS FSGS CLINICAL STUDY For personal use only @ Dimerix
Slide 14: Key mechanisms that cause sclerotic kidney disease
3 key mechanisms that cause sclerotic kidney disease For personal use only AT1R — blocked by angiotensin receptor blocker (ARB) CCR2-—CCR2 is the receptor for aa MCP-1; DMX-200 inhibits CCR2 to block attraction of inflammatory cells into the kidneys? Hyperfiltration of and hypertension within blood
Slide 15: DMX-200 — working on inflammatory signalling pathway
DMX-200 — working on inflammatory signalling pathway CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR) only fo) 12) =) © New Chemical Entity status, 2 x 120mg capsule daily Consistently safe and well 4 clinical studies com
Slide 16: DMX-200: Phase 2 met primary and secondary endpoints
DMX-200: Phase 2 met primary and secondary endpoints : Average reduction in proteinuria after 16 weeks Clinically meaningful outcomes for patients treatment on DMX-200 versus placebo compared to standard of care alone in FSGS patients! For personal use only 0.0% 8 3 -5.0% fee & le 8 ps as = 2s 2s &
Slide 17: uMCR normalised to baseline over time
For personal use only uMCR normalised to baseline v time N=7, GeoMean 50% 1.5 uMCR normalised 0% 1.0 -50% 0.5 On placebo On active 0.0 0 5 10 15 Time (weeks) • ▪ ▪
Slide 18: ACTION3 Phase 3 clinical trial
O ACTI IN3 Phase 3 clinical trial FSGS CLINICAL STUDY randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB Part 1: Part 2: Part 3: oe 72 patients @ 35 weeks treatment 144 patients @ 35 weeks treatment All patients @ 104
Slide 19: For personal use only
For personal use only • • • • • • • • •
Slide 20: ACTION3 Part 1 interim analysis set for Q1 2024
O ACTICIN3 Part 1 interim analysis set for Q1 2024 FSGS CLINICAL STUDY Announcement of interim analysis of Phase 3 trial expected on, or around, 15 March 2024* A successful outcome would see the Company announce a Clinically significant and statistical meaningful improvement in proteinuria vs placeb
Slide 21: Late stage, phase 3 clinical development asset
Late stage, phase 3 clinical development asset Orphan Drug status providing protection through data exclusivity? for min 7-10 years, in addition to comprehensive patent/IP strategy Near term Phase 3 interim analysis results announced (“15Mar24') Advanced partnering Estimated >3b global market negoti
Slide 22: For personal use only
For personal use only
Slide 23: Advancing the broader pipeline
Advancing the broader pipeline Additional longer term pipeline opportunities diversify risk and potential sources of revenue DMX-700 for Chronic DMX-200 for Diabetic Undisclosed Opportunities Obstructive Pulmonary Kidney Disease Disease (COPD) Preclinical studies show that DMX-700 Phase 2 demonstrat
Slide 24: Corporate overview
Corporate overview SHARE PRICE issue For personal use only Holder Name Holding 1 Mr Peter Meurs, 64,929,440 16.7% 2 Mr Andrew Coates & Mrs Melinda Coates 11,613,500 3.0% 3 Philip & Julie Scott 9,546,667 2.5% 4 FREEDOM TRADER PTY LTD 9,432,763 2.4% 5 BAVARIA BAY PTY LTD 7,316,992 1.9% QBAsx Ticker Sy
Slide 25: For personal use only
For personal use only Nina Webster Hugh Alsop Sonia Poli Clinton Snow PhD, MBA, M.IP.Law BSc (Hons), MBA PhD BEng (Hons), BCom CEO & Managing Director Non-Executive Director Non-Executive Director Non-Executive Director Wyeth (Pfizer), Acrux, Immuron Mayne Pharma, Acrux, Hatchtech, Hoffman la Roche,
Slide 26: For personal use only
For personal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN ESG Statement SCAN ME Dimerix HQ 42